Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 885-891

  Arsov, Stefan ^a   Graaff, Reindert ^a   Morariu, Aurora M ^a   Van Oeveren, Wim ^a   Smit, Andries J ^b   Busletic, Irena ^c   Trajcevska, Lada ^c   Selim, Gjulsen ^c   Dzekova, Pavlina ^c   Stegmayr, Bernd ^d   Sikole, Aleksandar ^c   Rakhorst, Gerhard ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c SS CYRIL AND METHODIUS UNIVERSITY   (Macedonia)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Advanced glycation end products; Cardiovascular disease; Haemodialysis; Hepatitis C; Skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BIOLOGICAL MARKER; HEPATITIS C ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; LIVER ENZYME;

ADULT; ARTICLE; AUTOFLUORESCENCE; BIOACCUMULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

AGE FACTORS; AGED; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; DIABETES COMPLICATIONS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; KIDNEY FAILURE, CHRONIC; LIVER; MALE; MIDDLE AGED; OXIDATIVE STRESS; REGRESSION ANALYSIS; RENAL DIALYSIS; RISK FACTORS; SKIN;

EID: 77649198841     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp564     Document Type: Article

References (37)

1. Amann K, Tyralla K, Gross ML, et al. Special characteristics of atherosclerosis in chronic renal failure. Clin Nephrol 2003; 60: S13-S21
2. Johnson DW, Craven AM, Isbel NM. Modification of cardiovascular risk in hemodialysis patients: an evidence-based review. Hemodial Int 2007; 11: 1-14
3. U.S. Renal Data System U2. Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States 2008Bethesda, MDNational Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases
4. Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505-521
5. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35-47
6. Wreghitt TG. Blood-borne virus infections in dialysis units-a review. Rev Med Virol 1999; 9: 101-109
7. Nakayama E, Akiba T, Marumo F, et al. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-1902
8. Stehman-Breen CO, Emerson S, Gretch D, et al. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis 1998; 32: 629-634
9. Di NA, Pezzotti P, Di LD, et al. Epidemiology of hepatitis C virus among long-term dialysis patients: a 9-year study in an Italian region. Am J Kidney Dis 2006; 48: 629-637
10. Fabrizi F, Takkouche B, Lunghi G, et al. The impact of hepatitis C virus infection on survival in dialysis patients: meta-analysis of observational studies. J Viral Hepat 2007; 14: 697-703
11. Caliskan Y, Oflaz H, Pusuroglu H, et al. Hepatitis C virus infection in hemodialysis patients is not associated with insulin resistance, inflammation and atherosclerosis. Clin Nephrol 2009; 71: 147-157
12. Oyake N, Shimada T, Murakami Y, et al. Hepatitis C virus infection as a risk factor for increased aortic stiffness and cardiovascular events in dialysis patients. J Nephrol 2008; 21: 345-353
13. Kalantar-Zadeh K, McAllister CJ, Miller LG. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005; 20: 1662-1669
14. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol 2007; 18: 1584-1593
15. Meerwaldt R, Zeebregts CJ, Navis G, et al. Accumulation of advanced glycation end products and chronic complications in ESRD treated by dialysis. Am J Kidney Dis 2009; 53: 138-150
16. Sakata N, Meng J, Takebayashi S. Effects of advanced glycation end products on the proliferation and fibronectin production of smooth muscle cells. J Atheroscler Thromb 2000; 7: 169-176
17. Meerwaldt R, Graaff R, Oomen PH, et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004; 47: 1324-1330
18. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3687-3693
19. Dripps RD. New classification of physical status. Anesthesiology 1963; 24
20. Clinical practice guidelines for hemodialysis adequacy, update 2006 2006New York, NYNational Kidney Foundation
21. International classification of disease and related health problems 10th revision 2009WHO/DIMDI
22. Hypertension diagnosis and treatment (guideline) 2008Bloomington, MNInstitute for Clinical Systems Improvement
23. American Diabetic Association. Revisions for the 2004 Clinical Practice Recommendations. Diabetes Care 2004; 27
24. Peskin AV, Winterbourn CC. A microtiter plate assay for superoxide dismutase using a water-soluble tetrazolium salt (WST-1). Clin Chim Acta 2000; 293: 157-166
25. Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci 2005; 1043: 299-307
26. Matsumoto T, Tsurumoto T, Baba H, et al. Measurement of advanced glycation endproducts in skin of patients with rheumatoid arthritis, osteoarthritis, and dialysis-related spondyloarthropathy using non-invasive methods. Rheumatol Int 2007; 28: 157-160
27. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up. World J Gastroenterol 2004; 10: 2209-2212
28. Akiyama S, Inagaki M, Tsuji M, et al. mRNA study on Cu/Zn super-oxide dismutase induction by hemodialysis treatment. Nephron Clin Pract 2005; 99: c107-c114
29. Koken T, Serteser M, Kahraman A, et al. Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol 2002; 15: 302-307
30. Nascimento MM, Suliman ME, Bruchfeld A, et al. The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 3112-3116
31. Horoz M, Bolukbas C, Bolukbas FF, et al. Oxidative stress in hepatitis C infected end-stage renal disease subjects. BMC Infect Dis 2006; 6: 114
32. Butscheid M, Schafer C, Brenner S, et al. Unchanged serum levels of advanced glycation endproducts in patients with liver disease. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 401-406
33. Gorka J, Zuwala-Jagiello J, Pazgan-Simon M, et al. Fluorescence of age in serum in detecting liver cirrhosis and hepatocellular carcinoma among patients with anti-HCV antibodies. Przegl Epidemiol 2008; 62: 393-400
34. Pawlak K, Pawlak D, Mysliwiec M. Impaired renal function and duration of dialysis therapy are associated with oxidative stress and proatherogenic cytokine levels in patients with end-stage renal disease. Clin Biochem 2007; 40: 81-85
35. Diurnal variation of circulating myeloperoxidase levels in patients with ST-segment elevation myocardial infarction. Int J Cardiol 2009
36. Sabry AA, Elbasyouni SR, Kalil AM, et al. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythe-matosus. Nephrology (Carlton) 2006; 11: 329-335
37. Oktay B, Akbal E, Firat H, et al. Evaluation of the relationship between heart type fatty acid binding protein levels and the risk of cardiac damage in patients with obstructive sleep apnea syndrome. Sleep Breath 2008; 12: 223-228